What is the level of liabilities of Metabiomed Co this year?
Metabiomed Co has a debt balance of 60.08 B KRW this year.
In 2024, Metabiomed Co's total liabilities amounted to 60.08 B KRW, a -0.67% difference from the 60.48 B KRW total liabilities in the previous year.
Metabiomed Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Metabiomed Co's financial stability, operational efficiency, and long-term viability.
By comparing Metabiomed Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Metabiomed Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Shifts in Metabiomed Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Metabiomed Co has a debt balance of 60.08 B KRW this year.
The liabilities of Metabiomed Co have increased by -0.67% dropped compared to the previous year.
High liabilities can pose a risk for investors of Metabiomed Co, as they can weaken the company's financial position and impair its ability to meet its obligations.
Low liabilities mean that Metabiomed Co has a strong financial position and is able to meet its obligations without overburdening its finances.
An increase in liabilities of Metabiomed Co can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
A decrease in the liabilities of Metabiomed Co can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
Some factors that can influence the liabilities of Metabiomed Co include investments, acquisitions, operating costs, and sales development.
The liabilities of Metabiomed Co are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
To change its liabilities, Metabiomed Co can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
Over the past 12 months, Metabiomed Co paid a dividend of 20 KRW . This corresponds to a dividend yield of about 0.52 %. For the coming 12 months, Metabiomed Co is expected to pay a dividend of 20 KRW.
The current dividend yield of Metabiomed Co is 0.52 %.
Metabiomed Co pays a quarterly dividend. This is distributed in the months of January, January, January, January.
Metabiomed Co paid dividends every year for the past 16 years.
For the upcoming 12 months, dividends amounting to 20 KRW are expected. This corresponds to a dividend yield of 0.52 %.
Metabiomed Co is assigned to the 'Health' sector.
To receive the latest dividend of Metabiomed Co from 4/15/2024 amounting to 20 KRW, you needed to have the stock in your portfolio before the ex-date on 12/27/2023.
The last dividend was paid out on 4/15/2024.
In the year 2023, Metabiomed Co distributed 20 KRW as dividends.
The dividends of Metabiomed Co are distributed in KRW.
Our stock analysis for Metabiomed Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Metabiomed Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.